13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002026172
Total reported value
$791.3M
$791.3M
106 檔
12.0%
The Q3 2025 SEC filing reveals that Diadema Partners LP held a total portfolio value of $791.3M, covering 106 public equity positions.
In Q3 2025, Diadema Partners LP displayed an active expansion posture, initiating 58 new positions and adding to 24 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including JAZZ, SLNOEUR, QURE) accounted for 12.0% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 5.84% | -1.76% | EXIT | |
| 2 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 5.66% | — | +15.20% | |
| 3 | QURE | uniQure N.V. | Stock-Other | 4.48% | +1.50% | +188.18% | |
| 4 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 4.34% | — | +437.90% | |
| 5 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 4.02% | +3.36% | +203.23% | |
| 6 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 3.58% | +6.78% | NEW | |
| 7 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 3.41% | — | — | |
| 8 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.95% | +0.84% | +10.37% | |
| 9 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.56% | — | — | |
| 10 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.28% | — | +81.90% | |
| 11 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.17% | -0.13% | EXIT | |
| 12 | INCY | Incyte CORP | Stock-Healthcare | 2.17% | -1.43% | — | |
| 13 | NTLA | Intellia Therapeutics Inc | Stock-Other | 2.08% | -0.01% | — | |
| 14 | PCVX | Vaxcyte Inc | Stock-Other | 2.01% | +0.31% | +10.09% | |
| 15 | LLY | Eli Lilly & Co | Stock-Healthcare | 1.95% | +0.58% | -78.03% | |
| 16 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.95% | -3.19% | EXIT | |
| 17 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 1.86% | -0.86% | EXIT | |
| 18 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 1.77% | +0.51% | +25.00% | |
| 19 | HRMY | Harmony Biosciences Holdings | Stock-Other | 1.76% | -0.32% | — | |
| 20 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.75% | -1.08% | EXIT | |
| 21 | MNKD | Mannkind CORP | Stock-Other | 1.72% | -0.07% | +140.81% | |
| 22 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.67% | — | — | |
| 23 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.63% | -1.58% | EXIT | |
| 24 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 1.57% | — | — | |
| 25 | MRNA | Moderna Inc | Stock-Healthcare | 1.47% | -0.50% | +9.90% | |
| 26 | ASND | Ascendis Pharma A/S | Stock-Other | 1.40% | — | — | |
| 27 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.36% | — | — | |
| 28 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.36% | — | -59.85% | |
| 29 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.17% | — | — | |
| 30 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.16% | +0.03% | +19.16% | |
| 31 | COGT | Cogent Biosciences Inc | Stock-Other | 1.09% | +0.30% | -50.41% | |
| 32 | NKTR | Nektar Therapeutics | Stock-Other | 1.09% | — | +57.98% | |
| 33 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.05% | -1.63% | EXIT | |
| 34 | UPB | Upstream Bio Inc | Stock-Other | 0.96% | -0.01% | — | |
| 35 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.95% | — | +58.92% | |
| 36 | ARCT | Arcturus Therapeutics Holdin | Stock-Other | 0.94% | — | — | |
| 37 | ABVX | Abivax Sa-adr | Stock-Other | 0.90% | +7.67% | — | |
| 38 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.87% | — | — | |
| 39 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.87% | — | -32.81% | |
| 40 | ZYME | Zymeworks Inc | Stock-Other | 0.86% | -0.14% | +9.59% | |
| 41 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.82% | — | +14.93% | |
| 42 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 0.74% | — | — | |
| 43 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.71% | -0.12% | -78.83% | |
| 44 | SCPH | Scpharmaceuticals Inc | Stock-Other | 0.67% | — | -34.39% | |
| 45 | REPL | Replimune Group Inc | Stock-Other | 0.66% | +0.68% | +1784.99% | |
| 46 | ABUS | Arbutus Biopharma CORP | Stock-Other | 0.60% | — | — | |
| 47 | ARDX | Ardelyx Inc | Stock-Other | 0.56% | +0.20% | NEW | |
| 48 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 0.56% | +1.11% | -73.55% | |
| 49 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.56% | -0.64% | -83.65% | |
| 50 | GOSS | Gossamer Bio Inc | Stock-Other | 0.55% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | QURE | uniQure N.V. | +4% | +188.18% | Add |
| 2 | VKTX | Viking Therapeutics Inc | +3.1% | +203.23% | Add |
| 3 | BMRN | Biomarin Pharmaceutical Inc | +2% | +10.37% | Add |
| 4 | AGIO | Agios Pharmaceuticals Inc | +1.4% | +81.90% | Add |
| 5 | ASND | Ascendis Pharma A/S | +1.1% | — | Add |
| 6 | MNKD | Mannkind CORP | +1% | +140.81% | Add |
| 7 | 430 | Terns Pharmaceuticals Inc | +1% | +30.33% | Add |
| 8 | CRSP | CRISPR Therapeutics AG | +0.9% | — | Unchanged |
| 9 | JAZZ | Jazz Pharmaceuticals plc | +0.7% | +12.08% | Add |
| 10 | PCVX | Vaxcyte Inc | +0.6% | +10.09% | Add |
| 11 | BBIO | Bridgebio Pharma Inc | +0.6% | — | Unchanged |
| 12 | CAPR | Capricor Therapeutics Inc | +0.5% | +181.43% | Add |
| 13 | REPL | Replimune Group Inc | +0.5% | +1784.99% | Add |
| 14 | SRRK | Scholar Rock Holding CORP | +0.5% | +58.92% | Add |
| 15 | MREO | Mereo Biopharma Group Pl-adr | +0.5% | +14.93% | Add |
| 16 | IMCR | Immunocore Holdings Plc-adr | +0.4% | +19.16% | Add |
| 17 | MRNA | Moderna Inc | +0.3% | +9.90% | Add |
| 18 | APGE | Apogee Therapeutics Inc | +0.3% | +14.85% | Add |
| 19 | ZYME | Zymeworks Inc | +0.3% | +9.59% | Add |
| 20 | SMMT | Summit Therapeutics Inc | +0.3% | -40.54% | Add |
| 21 | GOSS | Gossamer Bio Inc | +0.2% | — | Trim |
| 22 | URGN | UroGen Pharma Ltd. | +0.2% | -40.00% | Add |
| 23 | COGT | Cogent Biosciences Inc | +0.2% | -50.41% | Trim |
| 24 | OCUL | Ocular Therapeutix Inc | +0.2% | — | Unchanged |
| 25 | PCRX | Pacira Biosciences Inc | +0.1% | — | Add |
| 26 | OLMA | Olema Pharmaceuticals Inc | +0.1% | -64.32% | Trim |
| 27 | ✓ | Reviva Pharmaceutcls Hldgs I | +0.1% | -62.78% | Add |
| 28 | VTGN | Vistagen Therapeutics Inc | 0% | +11.35% | Trim |
| 29 | ✓ | Proqr Therapeutics N.v. | 0% | — | Trim |
| 30 | ATYR | Atyr Pharma Inc | 0% | — | Add |
| 31 | AM6 | Amicus Therapeutics Inc | 0% | — | Unchanged |
| 32 | ALEC | Alector Inc | -0.1% | -48.87% | Trim |
| 33 | RXRX | Recursion Pharmaceuticals-a | -0.1% | — | Unchanged |
| 34 | ALT | Altimmune Inc | -0.1% | -67.72% | Add |
| 35 | TRVI | Trevi Therapeutics Inc | -0.1% | -53.81% | Trim |
| 36 | RARE | Ultragenyx Pharmaceutical In | -0.1% | -28.35% | Add |
| 37 | FLNA | Filana Therapeutics Inc | -0.1% | — | Trim |
| 38 | CLYM | Climb Bio Inc | -0.1% | -80.56% | Trim |
| 39 | RLAY | Relay Therapeutics Inc | -0.3% | — | Trim |
| 40 | NBIX | Neurocrine Biosciences Inc | -0.4% | -59.85% | Trim |
| 41 | ANAB | Anaptysbio Inc | -1% | — | Trim |
| 42 | ALNY | Alnylam Pharmaceuticals Inc | -1.2% | — | Trim |
| 43 | TGTX | Tg Therapeutics Inc | -1.6% | -83.65% | Trim |
| 44 | NVO | Novo-nordisk A/s-spons Adr | -2.9% | +25.00% | Trim |
| 45 | REGN | Regeneron Pharmaceuticals | -3.9% | +437.90% | Trim |
| 46 | SLNOEUR | Soleno Therapeutics Inc | -4.2% | +15.20% | Trim |
| 47 | CORT | Corcept Therapeutics Inc | -5.1% | -73.55% | Trim |
| 48 | LLY | Eli Lilly & Co | -8.8% | -78.03% | Trim |
| 49 | AMGN | Amgen Inc | — | EXIT | Sold out |
| 50 | PFE | Pfizer Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Diadema Partners LP reported a total U.S. public equity portfolio value of $791.3M across 106 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
BMY
市值: $14.0M
Top Position Liquidated / Trimmed
AMGN
前期市值: $48.4M
During Q3 2025, Diadema Partners LP's top holdings by market value included JAZZ (5.8%)、SLNOEUR (5.7%)、QURE (4.5%). The largest single position, JAZZ, represented 5.8% of total portfolio value.
In Q3 2025, Diadema Partners LP made 125 total portfolio adjustments, initiating 58 new buys, adding to 24 positions, trimming 19 holdings, and fully liquidating 24 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.